Literature DB >> 17227117

Agranular CD4+/CD56+ hematodermic neoplasm: a distinct entity described in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas.

Firouzeh Niakosari1, Monalisa Sur.   

Abstract

Agranular CD4+/CD56+ hematodermic neoplasm is a distinct form of lymphoma with aggressive behavior and marked predilection for cutaneous involvement. Because of CD56 positivity, natural killer cells were initially suggested as the cell of origin in this tumor. In the recent World Health Organization-European Organization for Research and Treatment of Cancer classification, the term blastic natural killer cell lymphoma has been replaced with CD4+/CD56+ hematodermic neoplasm because of its derivation from a plasmacytoid dendritic cell precursor. Clinicopathologic features, immunohistochemical features, and differential diagnosis of this rare neoplasm with emphasis on the recent World Health Organization-European Organization for Research and Treatment of Cancer classification are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17227117     DOI: 10.5858/2007-131-149-ACHNAD

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  3 in total

1.  CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis.

Authors:  Kyu-Won Choi; Ki-Yeol Lee; Yeong-Kyu Lee; Bon-Seok Ku; Hong-Seok Kim; Young-Hun Kim; Ki-Ho Kim
Journal:  Ann Dermatol       Date:  2010-05-18       Impact factor: 1.444

2.  Blastic plasmacytoid dendritic cell neoplasm presenting as a subcutaneous mass in an 8-year-old boy.

Authors:  David Nizza; Stephen F Simoneaux
Journal:  Pediatr Radiol       Date:  2010-06-16

3.  Uncommon cases of immature-type CD56+ natural killer (NK)-cell neoplasms, characterized by expression of myeloid antigen of blastic NK-cell lymphoma.

Authors:  Satsuki Owatari; Maki Otsuka; Taketsugu Takeshita; Kyoko Mizukami; Sinsuke Suzuki; Kimiharu Uozumi; Yukie Tashiro; Naomichi Arima; Shuichi Hanada
Journal:  Int J Hematol       Date:  2008-12-25       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.